- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02245815
Prevention of Necrotizing Enterocolitis of Premature Newborns Under Less Than 1500 g Using Probiotics ((PEPP))
The Use of Probiotics (L. Acidophilus Boucardii vs. Multi-species) in the Prevention of Necrotizing Enterocolitis and Their Effect on Secreting IgA in the Feces of Premature Newborns Under Less Than 1500 g
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomized controlled trial, in the Neonatal department of Highly Specialized Medical Unit (UMAE) of Hospital Pediatric - Gynecology No. 48 of Mexican Institute of Social Security (IMSS ) on Leon, Mexico, between 15th of December 2013 and 30th of October 2014, on premature newborns of less than 1500 g. They were two groups of patients:
Group A: was given Lacteol fort, which contains 1x10⁹(CFU) of Lactobacillus acidophilus strain boucardii every 24 hours during 3 weeks. Its presentation is a powder of 160 mg. It's manufactured by (Carnot ® laboratories), scientific products .
Group B: was given multispecies probiotic, which contains 1x10⁹ (CFU) of Lactobacillus acidophilus, rhamnosus, casei, plantarum, Bifidobacterium infantis, Streptococcus thermophilus , every 24 hours during 3 weeks. Its presentation is a powder with 1. (ITALMEX laboratories), scientific products .
All patients received trophic enteral stimulation for 5 days, then an increasing amount of 12-20 ml/kg of breast milk on a daily basis, according to the Clinical Practice Guidelines of feeding premature newborns of the investigators hospital.
The envelops containing the probiotic they were labeled with patient data and handled to the nurse in charge of the feeding so that it can be added preferably to the prescribed breast milk, and administered at12 o´clock every day with the feeding.
The diagnosis of Necrotizing Enterocolitis (NEC) was made by the attending physician using Bell criteria. Moreover the attending physician did the adjustments in the amount of breast milk consumed by the patient.
Gastric tolerance will be observed through: the presence of vomit, abdominal distention, presence of blood or bile juice on the gastric tube, and the pattern and characteristics of the feces using a daily record.Stool samples were taken between 9 am. and 21:00., before the first administration of probiotics and at the end of the third week of probiotic treatment. The samples were processed and frozen at -70'C. Quantifying secrete immunoglobulin A (IgA s) was made by immunodiagnostic assay K8870, Benshein, Germany ELISA.
was monitored the clinical evolution of Necrotizing Enterocolitis (NEC), medical or surgical treatment and the complications.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guanajuato
-
Leon, Guanajuato, Mexico, 37000
- University of Guanajuato School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All of the premature newborns of 34 weeks of gestational age, and with a weight between 700 to 1500 g. that are admitted in the Neonatal Intensive Care Unit or the Neonatology Department that have no contraindication for oral intake in the first 7 days of life. Must not have been diagnosed of sepsis of early onset, prenatal asphyxia, patent ductus arterious with hemodynamic repercussion, major congenital malformations. In all cases the parents or legal guardian must sign the informed consent.
Exclusion Criteria:
- All preterm newborns younger than 34 weeks of gestational age that develop any disease different of (NEC) that require to stop the enteral feeding for more than seven days or whose parents or legal guardians revoke the informed consent form.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: use probiotics boucardii
was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
|
group A was administered the lactobacillus acidophilus boucardii probiotic (1x10⁹ colonies forming units (UFC) per day for 3 weeks).
The diagnosis of (NEC) was made using the Bell criteria by the attending physician.
Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.
|
Experimental: use probiotics Multi-species
was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
|
Group B was administered multi-species probiotic (1x10⁹colonies forming units (UFC) per day for 3 weeks).
The diagnosis of (NEC) was made using the Bell criteria by the attending physician.
Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With (NEC)
Time Frame: 3 weeks
|
(NEC) was evaluated according to Bell's criteria and only considered in case of stage II-III
|
3 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Guadalupe Gómez Rodríguez, M.D., University of Guanjuato
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R-2013-1002-7
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infectious Diseases
-
Central Hospital, Nancy, FranceEnrolling by invitationInfectious; Spondylitis
-
National Institute of Allergy and Infectious Diseases...RecruitingOccupational Accidents | Incubation Period, Infectious DiseseUnited States
-
Invirsa, Inc.Biomedical Advanced Research and Development AuthorityRecruitingAcute Infectious KeratoconjunctivitisUnited States, Thailand
-
Groupe Hospitalier Diaconesses Croix Saint-SimonFondation Ophtalmologique Adolphe de RothschildCompletedArthritis, Infectious | Bone Diseases, InfectiousFrance
-
Carecubes, Inc.University of NebraskaCompletedInfectious DiseasesUnited States
-
King Saud Medical CityUnknown
-
BayerCompletedInfectious DiseasesItaly
-
Universidad de GuanajuatoAntisepsia CentralCompleted
-
LG Life SciencesCompleted
-
Cosmo Technologies LtdCompletedInfectious Diarrhoea
Clinical Trials on use probiotics boucardii
-
Coordinación de Investigación en Salud, MexicoCompletedInfectious DiseasesMexico
-
Glac Biotech Co., LtdCompletedMetabolic SyndromeTaiwan
-
TCI Co., Ltd.Recruiting
-
University of Milano BicoccaCompleted
-
Arkansas Children's Hospital Research InstituteCompleted
-
Chr HansenAarhus University HospitalCompletedInfant Development | Gut MicrobiomeDenmark
-
Zealand University HospitalHolbaek Sygehus; Chr Hansen; Dept. of Microbiology, Slagelse University Hospital... and other collaboratorsCompleted
-
National Cheng-Kung University HospitalNational Science Council, TaiwanUnknownGastrointestinal Function | Intestinal Bacteria FloraTaiwan
-
Chung Shan Medical UniversityTCI Co., Ltd.Recruiting
-
Prof. Jacques SCHRENZELCompleted